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Abstract
Background: The mechanisms involved in the induction and regulation of inflammation resulting
in dopaminergic (DA) neurotoxicity in Parkinson's disease (PD) are complex and incompletely
understood. Microglia-mediated inflammation has recently been implicated as a critical mechanism
responsible for progressive neurodegeneration.
Methods: Mesencephalic neuron-glia cultures and reconstituted cultures were used to investigate
the molecular mechanisms of sinomenine (SN)-mediated anti-inflammatory and neuroprotective
effects in both the lipopolysaccharide (LPS)- and the 1-methyl-4-phenylpyridinium (MPP+)-mediated
models of PD.
Results: SN showed equivalent efficacy in protecting against DA neuron death in rat midbrain
neuron-glial cultures at both micro- and sub-picomolar concentrations, but no protection was seen
at nanomolar concentrations. The neuroprotective effect of SN was attributed to inhibition of
microglial activation, since SN significantly decreased tumor necrosis factor-α (TNF-α,
prostaglandin E2 (PGE2) and reactive oxygen species (ROS) production by microglia. In addition,
from the therapeutic point of view, we focused on sub-picomolar concentration of SN for further
mechanistic studies. We found that 10-14 M of SN failed to protect DA neurons against MPP+-
induced toxicity in the absence of microglia. More importantly, SN failed to show a protective effect
in neuron-glia cultures from mice lacking functional NADPH oxidase (PHOX), a key enzyme for
extracellular superoxide production in immune cells. Furthermore, we demonstrated that SN
reduced LPS-induced extracellular ROS production through the inhibition of the PHOX cytosolic
subunit p47phoxtranslocation to the cell membrane.
Conclusion: Our findings strongly suggest that the protective effects of SN are most likely
mediated through the inhibition of microglial PHOX activity. These findings suggest a novel therapy
to treat inflammation-mediated neurodegenerative diseases.
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Increasing evidence has shown that the production and
accumulation of pro-inflammatory and cytotoxic factors
by over-activated microglia are closely associated with the
pathogenesis of several neurological disorders, such as
Parkinson's disease (PD), Alzheimer's disease, amyo-
trophic lateral sclerosis, multiple sclerosis, and the AIDS
dementia complex [1-4]. Microglia are the main immune
cells in the brain, which provides the CNS immune pro-
tection against infection under normal physiologic condi-
tions [5]. However, in pathological conditions microglia
may easily become over-activated and produce large
amounts of pro-inflammatory factors, such as cytokines,
prostaglandins, and reactive oxygen species (ROS), which
result in neuronal death [6-8]. Microglia are found in
great abundance in the midbrain region that encompasses
the substantia nigra [9]. Thus, it has been suggested that
activation of nigral microglia and subsequent release of
these pro-inflammatory neurotoxic factors is a critical
component of the degenerative process of dopaminergic
(DA) neurons in PD. Unfortunately, therapies using spe-
cific inhibitors to prevent the production of individual
pro-inflammatory and neurotoxic factors have not been
particularly successful, suggesting that the mechanism of
inflammation-mediated damage to DA neurons has yet to
be elucidated. In addition, current DA replacement ther-
apy for PD is only able to treat the symptoms, and fails to
slow down the progression of the disease. Therefore, there
is an urgent need to develop drugs that have wide spec-
trum anti-inflammatory effects and which are able to slow
down or curtail the progression of the degenerative proc-
ess.
The alkaloid sinomenine (SN) is a pure compound
extracted from the Chinese medicinal plant, sinomenium
acutum, which has been utilized to treat inflammatory dis-
eases for many centuries [10,11]. Clinical trials have dem-
onstrated that purified SN has significant therapeutic
efficacy for patients who suffer from rheumatoid arthritis
[10,12]. Previous pharmacological studies have demon-
strated that the pharmacological profile of SN includes
immunosuppression [13], arthritis amelioration [14],
anti-inflammation [15] and protection against hepatitis
induced by lipopolysaccharide (LPS) [16]. In addition, in
studies using intramuscular injection and multiple dos-
ing, a combination of SN and cyclosporin A showed
immunomodulatory effects in a cardiac transplant model
[17]. Up to now, little is known about the molecular
mechanism by which SN exhibits immunomodulatory
effects.
Based on its molecular structure, SN belongs to the family
of morphinans. Morphinans are a series of compounds
structurally similar to morphine, but lacking the E ring as
well as the 6-OH and the 7, 8-double bond. Our previous
studies have clearly shown that several morphinan com-
pounds, including naloxone [18] and dextromethorphan
[19], are neuroprotective anti-inflammatory agents. Given
the reported anti-inflammatory properties of SN, the
record of its effective use in clinical therapy, its natural
abundance, and its relative low cost in purification and
preparation, we theorized that this compound might be a
better alternative than synthetic morphinan compounds
in inhibiting inflammatory destruction of DA neurons.
Moreover, the finding that it is a naturally occurring dex-
trorotatory morphinan isomer indicates that it would
have minimal interaction with opiate receptors, and
therefore prove to be a much safer alternative than some
other morphinan compounds when used chronically to
treat PD. In this study, we report that SN shows a signifi-
cant neuroprotective effects against both LPS- and MPP+-
induced DA neurotoxicity, and that this protection is
mediated through microglia. The finding that SN is acting
to inhibit NADPH oxidase (PHOX) activity, which then
results in the inhibition of a wide array of pro-inflamma-
tory mediators produced by activated microglia, suggests
that SN may be a potential novel and safe therapeutic




PHOX-deficient (gp91phox-/-) and wild-type C57BL/6J
(gp91phox+/+) mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME). Breeding of the mice was per-
formed to achieve timed pregnancy with the accuracy of ±
0.5 days. Timed-pregnant Fisher F344 rats were obtained
from Charles River Laboratories (Raleigh, NC). Housing
and breeding of the animals were performed in strict
accordance with the National Institutes of Health guide-
lines.
Reagents
SN was obtained from Sigma-Aldrich (St. Louis, MO). LPS
(strain O111:B4) was purchased from Calbiochem (San
Diego, CA). Cell culture reagents were obtained from Inv-
itrogen (Carlsbad, CA). [3H]-DA (30 Ci/mmol) was
obtained from Perkin-Elmer Life Sciences (Boston, MA),
and the polyclonal anti-tyrosine hydroxylase antibody
was a generous gift from Dr. John Reinhard (GlaxoSmith-
Kline, Research Triangle Park, NC). The Vectastain ABC kit
and biotinylated secondary antibodies were purchased
from Vector Laboratories (Burlingame, CA). The fluores-
cence probe Dichlorodihydro-fluorescein Diacetate
(DCFH-DA) was obtained from Calbiochem (La Jolla,
CA).
Microglial cell line
The rat microglia HAPI cell line was a generous gift from
Dr. James R. Connor [20]. Briefly, cells were maintainedPage 2 of 14
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penicillin, and 50 µg/ml streptomycin in a humidified
incubator with 5% CO2 and 95% air.
Primary mesencephalic neuron-glia culture
Neuron-glia cultures were prepared from the ventral mes-
encephalic tissues of embryonic day 14–15 rats or day 13–
14 mice, as described previously [18]. Briefly, dissociated
cells were seeded at 1 × 105/well and 5 × 105/well to poly-
D-lysine-coated 96-well and 24-well plates respectively.
Cells were maintained at 37°C in a humidified atmos-
phere of 5% CO2 and 95% air, in MEM containing 10%
fetal bovine serum, 10% horse serum, 1 g/L glucose, 2 mM
L-glutamine, 1 mM sodium pyruvate, 100 µM nonessen-
tial amino acids, 50 U/ml penicillin, and 50 µg/ml strep-
tomycin. Seven-day-old cultures were used for treatment.
At the time of treatment, immunocytochemical analysis
indicated that the rat neuron-glia cultures were made up
of 11% microglia, 48% astrocytes, 41% neurons, and 1%
tyrosine hydroxylase immunoreacitve (TH-IR) neurons.
The composition of the neuron-glia cultures of PHOX-
deficient mice was very similar to that of the wild-type
mice consisting of 12% microglia, 48% astrocytes, 40%
neurons, and 1% TH-IR neurons.
Primary mesencephalic neuron-enriched and microglia-
enriched Cultures
Midbrain neuron-enriched cultures were established as
described previously [21]. Briefly, 24 h after seeding the
cells, cytosine β-D-arabinocide was added to a final con-
centration of 5 µM to suppress glial proliferation. Three
days later, cultures were changed back to maintenance
medium and were used for treatment 7 days after initial
seeding. Rat microglia-enriched cultures, with a purity of
> 98%, were prepared from whole brains of 1-day-old
Fischer 344 rat pups as described previously [21].
[3H]-DA uptake assay
[3H]-DA uptake assays were performed as described [22].
Briefly, cells were incubated for 20 min at 37°C with 1 µM
[3H]-DA in Krebs-Ringer buffer (16 mM sodium phos-
phate, 119 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2
mM MgSO4, 1.3 mM EDTA, and 5.6 mM glucose; pH 7.4).
After washing three times with ice-cold Krebs-Ringer
buffer, the cells were collected in 1 N NaOH. Radioactivity
was determined by liquid scintillation counting. Nonspe-
cific DA uptake observed in the presence of mazindol (10
µM) was subtracted.
Immunostaining
DA neurons were recognized with the anti-TH antibody as
described previously [21]. Briefly, formaldehyde (3.7%)-
fixed cultures were treated with 1% hydrogen peroxide
(10 min) followed by sequential incubation with block-
ing solution for 30 min, primary antibody overnight at
4°C, biotinylated secondary antibody for 2 h, and ABC
reagents for 40 min. Color was developed with 3,3'-diami-
nobenzidine. For morphological analysis, the images
were recorded with an inverted microscope (Nikon,
Tokyo, Japan) connected to a charge-coupled device cam-
era (DAGE-MTI, Michigan City, IN) operated with the
MetaMorph software (Universal Imaging Corporation,
Downingtown, PA). For visual counting of TH-IR neu-
rons, nine representative areas per well of the 24-well
plate were counted under the microscope at 100 × magni-
fication by three individuals. The average of these scores
was reported.
Nitrite and tumor necrosis factor (TNF-α assays)
The production of NO was determined by measuring the
accumulated levels of nitrite in the supernatant with
Griess reagent and the release of TNF-α was measured
with a rat TNF-α enzyme-linked immunosorbent assay kit
from R and D System (Minneapolis, MN, USA), as
described [23].
Prostaglandin E2 (PGE2) production
PGE2 in supernatant was measured with a PGE2 EIA kit
from Cayman (Ann Arbor, MI, USA) according to the
manufacturer's instructions.
Superoxide assay
The production of superoxide was determined by measur-
ing the superoxide dismutase (SOD)-inhibitable reduc-
tion of the tetrazolium salt WST-1 [24,25]. Microglia-
enriched cultures in 96-well culture plates were washed
twice with HBSS without phenol red. Cultures were then
incubated at 37°C for 30 min with vehicle control (water)
or SN in HBSS (50 µl/well). Then, 50 µl of HBSS with and
without SOD (50 U/ml, final concentration) was added to
each well along with 50 µl of WST-1 (1 mM) in HBSS, and
50 µl of vehicle or LPS (10 ng/ml). To measure superoxide
production induced by 0.2 uM MPP+, seven days-old mes-
encephalic neuron-glia cultures grown in 96-well plates
were treated with SN in the presence or absence of MPP+,
or vehicle in 150 µl of phenol red-free treatment medium.
Four days after treatment, 50 µl of HBSS with and without
SOD (50 U/ml, final concentration) was added to each
well along with 50 µl of WST-1 (1 mM) in HBSS. Fifteen
minutes later, absorbance at 450 nm was read with a Spec-
traMax Plus microplate spectrophotometer (Molecular
Devices Corp, Sunnyvale, CA). The difference in absorb-
ance observed in the presence or absence of SOD was con-
sidered to be the amount of superoxide produced, and
results were expressed as percentage of vehicle-treated
control cultures.
Assay of intracellular reactive oxygen species
Intracellular oxidative stress was measured by DCFH Oxi-
dation[26]. DCFH-DA enters cells passively and isPage 3 of 14
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reacts with ROS to form dichlorodifluorescein, the fluo-
rescent product. DCFH-DA was dissolved in methanol at
10 mM and was diluted 500-fold in HBSS to give DCFH-
DA at 20 µM. The cells were exposed to DCFH-DA for 1 h
and then treated with HBSS containing the corresponding
concentrations of LPS for 2 h. The fluorescence was read
immediately at wavelengths of 485 nm for excitation and
530 nm for emission using a SpectraMax Gemini XS fluo-
rescence microplate reader (Molecular Devices). The value
subtracted by control group was viewed as the increase of
intracellular ROS.
Real time RT-PCR analysis
Real time quantitative PCR was performed as described
previously [21], The relative differences between control
and treatment groups were calculated and expressed as
relative increases setting control as 100%. The sequence of
the oligonucleotide primers from rats were: TNF-α: 5'-
TCGTAGCAAACCACCAAGCA-3' and 5'-CCCTTGAAGA-
GAACCTGGGAGTA-3'; Inducible nitric oxide synthase
(iNOS): 5'-ACATCAGGTCGGCCATCACT-3', and 5'-
CGTACCGGATGAGCTGTGAATT-3'; Cyclo-oxygenases-2
(COX-2): 5'-CCAGCAG GCTCATACTGATAGGA-3' and
5'-GCAGGTCTGGGTCGAACTTG-3'; GAPDH: 5'-CCT-
GGAGAAACCTGCCAAGTAT-3' and 5'-AG CCCAGGAT-
GCCCTTTAGT-3'.
Confocal microscopy
Confocal analysis was performed as described previously
[21]. HAPI cells seeded in dish at 5 × 104 cells/well were
treated with LPS for 10 min in the absence or presence of
SN (10-14 M) pretreatment for 30 min. Cells were fixed
with 3.7% paraformaldehyde in PBS for 10 min. After a
washing with PBS, cells were incubated with rabbit poly-
clonal antibody against p47phox. Cells were then washed
and incubated with FITC-conjugated goat anti-rabbit anti-
body. Focal planes spaced at 0.4-µm intervals were
imaged with a Zeiss 510 laser scanning confocal micro-
scope (63 × PlanApo 1.4 numerical aperture objective)
equipped with LSM510 digital imaging software. The sig-
nal of p47phox (FITC-p47phox; green) and the merge view of
cell morphology and p47phox (Phase plus FITC-p47phox) are
shown. Scale bar, 50 µm.
Membrane fractionation and western blot analysis
Membrane fractionation was performed as described
(34). HAPI cells were lysed in hypotonic lysis buffer (1
mM EGTA, 1 mM EDTA, 10 mM β-lycerophosphate, 10
mM NaF, 1 mM sodium orthovanadate, 2 mM MgCl2, 10
mM DTT, 1 mM PMSF, and 10 ug/ml each leupeptin,
aprotinin, and pepstatin A), incubated on ice for 30 min,
and then subjected to Dounce homogenization (20~25
stokes, tight pestle A). The lysates were loaded onto
sucrose in lysis buffer (final 0.5 M) and centrifuged at
1600 × g for 15 min, The supernatant above the sucrose
gradient was centrifuged at 150,000 × g for 30 min. The
resulting pellets were solubilized in 1% NP-40 hypotonic
lysis buffer and used as membranous fraction. Equal
amounts of protein (20 µg per lane) were separated by
4~12% Bis-Tris Nu-PAGE gel and transferred to polyvi-
nylidene difluoride membranes (Novex, San Diego, CA).
Membranes were blocked with 5% nonfat milk and incu-
bated with rabbit anti-p47phox antibody (1: 2000 dilution)
or mouse anti-gp91phox (1:1000 dilution) for 1 h at
25°C. Horseradish peroxidase-linked anti-rabbit or
mouse IgG (1:3000 dilution) for 1 h at 25°C, ECL+Plus
reagents (Amersham Biosciences Inc., Piscataway, NJ) was
used as a detection system.
Statistical analysis
The data are presented as mean ± SE. For multiple com-
parisons of groups, two-way ANOVA was used. Statistical
significance of differences between groups was assessed
using paired Student's t test, followed by Bonferroni cor-
rection using the JMP program (SAS Institute, Cary, NC,
USA). A value of P < 0.05 was considered statistically sig-
nificant.
Results
Effect of SN on LPS-induced DA neurotoxicity
We explored whether SN was neuroprotective at a wide
range of concentrations (10-17 to 10-5 M). Mesencephalic
neuron-glia cultures were pretreated with different con-
centrations of SN for 30 min before the addition of LPS
for 7 days. The LPS-induced damage of DA neurons was
then determined by [3H]-DA uptake assay (Fig. 1A) and by
counting the number of TH-IR neurons (Fig. 1B). The
[3H]-DA uptake assay showed that LPS treatment reduced
the capacity of the cultures to take up DA to approxi-
mately 56% of the vehicle control. Interestingly, we found
that both micromolar (10-6–10-5 M) and sub-picomolar
concentrations (10-14–10-13 M) of SN could prevent this
LPS-induced reduction. It is important to note that
nanomolar concentrations of SN (10-10–10-8 M) showed
no significant protective effects (Fig. 1A). Identical protec-
tive effects were observed when we measured the number
of viable TH-IR neurons with immunostaining (Fig. 1B).
Morphological analysis revealed that LPS treatment not
only decreased the number of TH-IR neurons, but also
caused a loss of neuronal process, and these characteristics
were also reversed by SN pretreatment in a concentration-
dependent manner (Fig. 1C).
SN pretreatment suppresses LPS-induced pro-
inflammatory factors production and gene expression
We have previously reported that microglia play a critical
role in mediating LPS-induced neurotoxicity [27]. LPS can
activate microglia to produce an array of pro-inflamma-
tory mediators, and among them ROS is the key factorPage 4 of 14
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Both micromolar and sub-picomolar concentrations of SN are neuroprotective against LPS-induced neurotoxicityFigure 1
Both micromolar and sub-picomolar concentrations of SN are neuroprotective against LPS-induced neurotoxicity. Rat primary 
mesencephalic neuron-glia cultures seeded in a 24-well culture plate with 5 × 105 rat midbrain cells, then pretreated with SN 
(10-17 to 10-5 M) for 30 min before the addition of 10 ng/ml LPS. Eight days later, the LPS-induced dopaminergic neurotoxicity 
was quantified by the [3H]-DA uptake assay (A); by immunocytochemical analysis, including TH-IR neuron counts (B); and by 
representative pictures of immunostained sections (C). Results are expressed as percentage of vehicle-treated control cultures 
and represent the mean ± SE. for four (A) or three (B, C) independent experiments in triplicate. The mean absolute values of 
[3H]-DA uptake for vehicle-treated cultures range from 5000 to 7000 cpm. *P < 0.05, **P < 0.01 compared with the LPS-
treated cultures.
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first tested the effect of SN on the LPS-induced ROS gener-
ation, including extracellular superoxide and intracellular
ROS in microglia-enriched cultures. As shown in Figs. 2A
and 2B, SN at 10-5 M and 10-14 M, but not 10-10 M, signif-
icantly attenuated LPS activation-mediated superoxide
production and levels of intracellular ROS. We further
investigated other pro-inflammatory mediators induced
by activated microglia, including TNF-α, PGE2, and
nitrite, all of which have been previously reported to be
neurotoxic [2]. Enriched microglia were pretreated with
vehicle or SN for 30 min before the addition of LPS. Three
hours after LPS stimulation, RNA was extracted and real-
time PCR assay was performed. As shown in Fig. 2C, both
micromolar and sub-picomolar concentrations of SN sig-
nificantly inhibited nitric oxide production and iNOS
mRNA expression and TNF-α protein production and
mRNA expression (Fig. 2D), as well as PGE2 production
and COX-2 mRNA expression (Fig. 2E) in enriched micro-
glia, while SN at 10-10 M showed no effect (Fig. 2). Since
both micromolar and sub-picomolar concentrations of
SN show equal potency in their neuroprotective effects by
inhibiting microglia activity, we focused only on sub-
picomolar concentration (10-14M) for further study.
SN also suppresses MPP+-induced neurotoxicity by 
inhibition of microglia activation
1-Methyl-4-phenylpyridinium (MPP+), the active metabo-
lite of MPTP, is known to damage DA neurons directly.
Since MPTP/MPP+ has been widely used in rodent PD
model, we sought to determine whether SN would inhibit
MPP+-induced neurotoxicity. Neuron-glial cultures were
pretreated with SN for 30 min, then incubated with 0.2
µM MPP+ for seven days, and neurotoxicity was assayed by
DA uptake. Addition of MPP+ resulted in a decrease in DA
uptake (reduced to 38% of control), and this toxicity was
partially but significantly reversed by pretreatment of
these cells with SN (recovered to 60% of control) (Fig. 3A
– NG). This indicates that sub-picomolar concentration of
SN protects against the neurotoxic effects of MPP+, but
there is a level of toxicity mediated by the direct toxic
effect by MPP+ on neurons that is independent of the pro-
tective effects of SN.
We then sought to determine the cellular target of SN-
mediated neuroprotection. Results showed that SN had
no effect on the toxic effects of MPP+ in neuron-enriched
cultures (Fig. 3A – N), demonstrating that SN does not
function by directly protecting neurons from MPP+-medi-
ated toxicity. We then investigated if glial cells were the
target for the neuroprotective activity of SN by reconstitut-
ing neuron-enriched cultures with either 10% purified
microglia (Fig. 3A – N + 10% MG) or 50% astroglia (Fig.
3A – N+50% AS). The percentage of glial cells chosen for
reconstitution was based on the fact that our standard
mesencephalic neuron-glia cultures contain ~10% micro-
glia and ~50% astrocytes in addition to DA and other neu-
rons. We found that while SN is not able to protect DA
neurons in neuron-astroglia reconstituted cultures, SN
was able to reduce neurotoxicity in neuron-microglia
reconstituted cultures to a level similar to that seen in the
original neuron-glia cultures. This result indicates that
there is an additional, indirect microglia-mediated neuro-
toxicity by MPP+ through reactive microgliosis, a process
initiated when the death or damage of neurons triggers
further activation of microglia [27].
Previous work from our laboratory and others have indi-
cated that oxidative stress plays a very important role in
the progressive neurodegeneration, and MPTP/MPP+-
induced reactive microgliosis has been clearly linked with
microglial activation and closely associated with
increased production of oxygen free radicals [27,29].
Therefore, we sought to determine whether SN is able to
reduce MPP+-induced ROS production. Rat mesen-
cephalic neuron-glia cultures were pretreated with SN (10-
14 M) before the addition of MPP+. Release of superoxide
from activated microglia was then determined on day 4
after treatment. As shown in Fig. 3B, treatment of cultures
with SN significantly inhibited MPP+-induced superoxide
production. Interestingly, we found that while significant
superoxide production was detected following MPP+-
induced reactive microgliosis, the production of other
inflammatory mediators, including TNF-α and nitrite,
were not detectable at any time during the 7-day MPP+
treatment in neuron-glial cultures (data not shown).
Taken together, these results demonstrated that SN can
inhibit ROS production induced either directly by LPS
stimulation or indirectly by MPP+-mediated reactive
microgliosis, and lend further evidence to the idea that
superoxide production, rather than TNF-α or nitrite pro-
duction, is the mechanism of neurotoxicity in reactive
microgliosis.
PHOX is essential for SN mediated neuroprotection
Previous reports from our laboratory indicated that PHOX
is the major enzyme in microglia that produces extracellu-
lar superoxide anions and is a major contributor to the
increase of the intracellular ROS, which in turn enhances
TNF-α production [28]. To further study the role of ROS
in SN-mediated neuroprotection, neuron-glia cultures
were prepared from PHOX-deficient (PHOX-/-) and wild-
type (PHOX+/+) mice. As shown in Fig. 4A, LPS treatment
of cultures prepared from PHOX+/+ mice reduced [3H]-DA
uptake by 50%, while SN (10-14 M) significantly attenu-
ated the decrease. In contrast, LPS treatment reduced the
uptake capacity by 27% in PHOX-/- mice, but SN failed to
show any protective effect. LPS-induced TNF-α produc-
tion in PHOX-/- mice is only half of that in PHOX+/+ mice,
and while SN was able to significantly reduce TNF-α pro-Page 6 of 14
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in PHOX-/- mice (Fig. 4B). Similarly, SN at 10-14 M signifi-
cantly inhibited intracellular ROS production in PHOX+/+
mice, but not in PHOX-/- mice (Fig. 4C). These results
strongly support the hypothesis that inhibition of ROS
production and subsequently TNF-α production is critical
to the neuroprotective effect of SN.
Previous studies have shown that activation of PHOX
activity requires that the cytosolic component of the
PHOX enzyme, p47phox, become phosphorylated and
translocate along with p67phox, and p40phox, to the plasma
membrane where it associates with cytochrome b558 and
assembles into an active enzyme [30]. Since SN signifi-
cantly inhibits superoxide production and fails to protect
Effect of SN on LPS-induced production of pro-inflammatory factors and their mRNA expressionFigure 2
Effect of SN on LPS-induced production of pro-inflammatory factors and their mRNA expression. Enriched microglia cells 
were pretreated with vehicle or SN (10-5, 10-10, and 10-14 M) for 30 min before LPS (10 ng/ml) stimulation. Effects of SN are 
shown on LPS-induced production of superoxide (A, expressed as % of control); and on intracellular ROS (B, expressed as 
absolute absorbance). Extracellular superoxide was measured as SOD-inhibitable reduction of WST-1, and intracellular ROS 
was determined by probe DCFH-DA. Supernatant was collected at 24 h for nitrite assay (C), at 3 h for TNF-α assay (D), and at 
24 h for PGE2 assay (E). RNA were extracted at 3 h after LPS stimulation; the effect of SN, at sub-picomolar concentrations, on 
LPS-induced iNOS, TNF-α, and COX-2 mRNA expression (C-E respectively, open bars) are shown. Results are expressed as 
mean ± SE for three independent experiments performed in triplicate. *P < 0.05, **P < 0.01 compared with the LPS-treated 
cultures.Page 7 of 14
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SN protects against MPP+-elicited DA neurodegeneration through microgliaFigu e 3
SN protects against MPP+-elicited DA neurodegeneration through microglia. SN (10-14 M) or MPP+ (0.2 µM) were added to the 
following types of cell cultures: (NG): original neuron-glial cultures; (N): neuron-enriched cultures; (N+10%MG): cultures 
reconstituted by adding 10% of microglia to the neuron-enriched cultures; (N+50%AS): cultures reconstituted by adding 50% 
of astroglia to the neuron-enriched cultures. Two and 4 days after MPP+ treatment, SN (10-14 M) was added again to the SN-
treated cultures. On day 8, the MPP+-induced dopaminergic neurotoxicity was quantified by the [3H]-DA uptake assay (A), and 
on day 4, the release of superoxide was determined as described in Materials and methods section. Results are expressed as 
percentage of the vehicle-treated control cultures and represent the mean ± SE. for three independent experiments per-
formed in triplicate. *P < 0.05, compared with MPP+ treated cultures. # P < 0.05, ## P < 0.01 compared with the vehicle-
treated control cultures.
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Microglial PHOX is critical for sub-picomolar SN neuroprotectionFigure 4
Microglial PHOX is critical for sub-picomolar SN neuroprotection. PHOX+/+ and PHOX-/- mouse neuron-glia cultures were 
pretreated with vehicle or SN (10-14 M) for 30 min, followed by LPS treatment. Neurotoxicity was assessed by measuring DA 
uptake (A), TNF-α production (B) and intracelluar ROS (C), respectively. Results are expressed as % of the control culture (A 
and C) and as pg/ml (B), and represent the mean ± SE for 3 individual experiments performed in triplicate in each experiment. 
*P < 0.05 compared with LPS culture. # P < 0.05, ## P < 0.01 compared with the vehicle-treated control cultures.
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sought to determine if SN inhibits PHOX activation by
preventing the p47phox translocation from cytosol to mem-
brane following LPS stimulation in HAPI cells, a micro-
glial cell line from rat. Using confocal microscopy, we
observed that in un-stimulated cells (Fig. 5, panel I and II)
or in cells treated with SN alone (Fig. 5, panel VII and
VIII), p47phox was found primarily localized in the cytosol.
In contrast, ten minutes after LPS stimulation, we detected
virtually all the p47phox clustered at the membrane (Fig. 5,
panel III and IV). However, the addition of 10-14 M SN sig-
nificantly prevented this LPS-induced p47phox transloca-
tion (Fig. 5, panel V and VI). Consistent with the results of
the confocal microscopy study, western blot assay clearly
showed an increase in the immunoreactivity of p47phox in
the membrane fraction of HAPI cells 10 min after LPS
treatment and this increase in the immunoreactivity was
significantly blocked in the presence of SN at 10-14 M. LPS
did not show any effects on gp91 protein expression at
this time point (Fig. 6). Therefore, one mechanism by
which SN inhibits superoxide production in microglial
cells is through inhibition of p47phox translocation to the
cell membrane following LPS stimulation.
Discussion
The main findings in this study are the elucidation of anti-
inflammatory and neuroprotective effects of SN at both
the cellular and molecular level. Using both LPS and
MPP+-mediated PD models, we are the first to demon-
strate that SN could be effective in diminishing inflamma-
tion-induced neurodegeneration at both micro- and sub-
picomolar concentrations in primary midbrain neuron-
glia cultures. Mechanistic studies revealed that inhibition
of microglial PHOX activity is the target for SN-mediated
neuroprotection in both LPS- and MPP+-induced DA neu-
rotoxicity. The mechanism underlying SN-mediated inhi-
bition of PHOX activity occurs at least in part through the
inhibition of the translocation of PHOX cytosolic compo-
nent p47phox to the plasma membrane, a key event
required for extracellular ROS production [31]. We are
currently investigating the effects of SN on the activity of
the other subunits of the PHOX enzyme, including
p67phox, p40phox, gp91phox, p22phox and Rac2. The inhibition
of PHOX leads to a subsequent reduction in the produc-
tion of other pro-inflammatory mediators, such as intrac-
ellular ROS, TNF-α, NO and PGE2. Our studies suggest
that reduction in PHOX activity by SN at the site of
inflammation diminishes host tissue damage, thereby
underlying the neuroprotective effect of SN for both LPS-
and MPP+-induced DA neurotoxicity.
Although SN has been used clinically as an anti-inflam-
matory agent in several inflammation-related diseases
[10,11], so far only a few studies have addressed the
immunomodulatory mechanism of this herbal medicine.
Immunofluorescence and confocal microscopical analysis of p47phox localizatio  in LPS-stimulated microlgia cellsFigure 5
Immunofluorescence and confocal microscopical analysis of 
p47phox localization in LPS-stimulated microlgia cells. HAPI 
cells were treated with LPS for 10 min in the absence or 
presence of SN pretreatment for 0.5 h. Cells were immunos-
tained with a rabbit polyclonal antibody against p47phox, then 
washed and incubated with FITC-conjugated goat anti-rabbit 
antibody. The signal of p47phox (FITC-p47phox; on left) and the 
merge view of cell morphology and p47phox (Phase plus FITC-
p47phox, on right) are shown. The inset shown in the right 
corner of each treatment condition shows the location of 
FITC-p47phox in a single, randomly selected cell. Focal planes 
spaced at 0.4-µm intervals were imaged with a Zeiss 510 
laser scanning confocal microscope (63 × PlanApo 1.4 
numerical aperture objective) equipped with LSM510 digital 
imaging software. Three adjacent focal planes were averaged 
using Metamorph software. The signal of p47phox (FITC-
p47phox; green) and the merge view of cell morphology and 
p47phox (Phase plus FITC-p47phox) are shown. Scale bar, 50 
µm.Page 10 of 14
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duction of pro-inflammatory mediators, such as TNF-α,
IL-1, PGE2, leukotriene C4 and NO from macrophages
[15,32,33]. Our observations have not only extended the
above findings to microglia, but more importantly, our
studies indicate that the reduction in the release of these
pro-inflammatory factors by SN could be due to the inhi-
bition of superoxide production through the inhibition of
microglial PHOX activity. Our earlier studies established
that inhibition of microglial production of superoxide
was most effective in protecting neurons, indicating that
superoxide was a dominant degenerative factor for the DA
neurons in the culture [18]. Our evidence that SN signifi-
cantly inhibits the production of superoxide induced by
either LPS or MPP+, as well as the observation that ROS
production is the only inflammatory mediator that can be
detected after exposure of neuron-glial cultures to MPP+,
led us to examine the role of PHOX in neurotoxicity in
greater detail by using PHOX-deficient mutant mice. Our
findings that sub-picomolar SN could significantly lessen
the LPS-induced DA uptake reduction in wild-type mice,
has no significant protective effect in PHOX-/- mice (Fig.
4A) strongly support the conclusion that PHOX activity is
critical to SN-mediated DA neuroprotection. Moreover,
the production of intracellular ROS and release of TNF-α
are both reduced in PHOX-/- mice, suggesting PHOX can
indirectly regulate intracellular ROS concentration and
ultimately the production of pro-inflammatory media-
tors. We can not rule out the possibility that cells other
than microglia are producing superoxide, and that PHOX
is not the only enzyme which may play a role in ROS pro-
duction. However, only microglia express LPS receptors
and are activated by LPS, and therefore no other cell is
likely to produce ROS upon stimulation with LPS. In addi-
tion, no extracellular superoxide production has been
detected in cultures from PHOX-/- mice (Qin et al., 2004),
suggesting that PHOX is the only enzyme involved in
superoxide production in these cultures. It has been found
that an increase of intracellular ROS can intensify the acti-
vation of NF-kB, which leads to higher TNF-α and PGE2
Membrane fraction analysis of the effect of SN on cytosolic p47phox protein translocationFigure 6
Membrane fraction analysis of the effect of SN on cytosolic p47phoxprotein translocation. HAPI cells were pre-
treated with vehicle or SN (10-14 M) for 30 min, followed by LPS treatment for 10 min. Membrane fractions were isolated to 
perform western blot analysis, using gp91phox as an internal membrane control. Each experiment was performed three times. *P 
< 0.05, compared with the LPS-treated cultures.Page 11 of 14
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PHOX inhibitors prevent LPS/IFNγ-induced degradation
of IkB and, thus, inhibit the activation of NF-kB [34].
These data are consistent with the notion that PHOX plays
a central role in both inflammation-induced neurotoxic-
ity, as well as in the regulation of the inflammatory
response by microglial cells, and that SN can inhibit these
inflammatory responses by inhibiting PHOX activity.
The bimodal dose response of SN in the inhibition of LPS-
induced superoxide production and neuroprotection adds
SN to the list of compounds which show the same pattern
of responsiveness, including dynorphins [35], enkepha-
lins [36], endorphin [37], pituitary adenylate cyclase-acti-
vating polypeptide (4–6) [38]. Currently it is still not clear
how both micro- and sub-picomolar concentrations of SN
and the other compounds inhibit PHOX activation. To
further understand how SN inhibits PHOX activity, we
performed the translocation experiment using confocal
microscopy. We found that the translocation of the
p47phox subunit from the cytosol to the plasma membrane
following LPS stimulation was inhibited by SN. As the
activation of a functional PHOX enzyme requires the
phorsphorylation of p47phox followed by the translocation
of the p47phox, p67phox, and p40phox complex to the plasma
membrane, our results suggest that SN works on one of
the earliest stages of PHOX activation to inhibit the
assembly of the PHOX enzyme complex. Presently the
molecular mechanisms by which SN leads to the inhibi-
tion of p47phox translocation are under investigation.
It is interesting to note that SN has protective effects in
both the LPS and the MPP+ model of PD, although the
mode of action for these two agents to produce neurotox-
icity is different. In the LPS model, it is clear that direct
activation of microglia by LPS leads to the activation of
PHOX, which results in the production of superoxide that
mediates the neurotoxicity, and that direct inhibition of
PHOX by SN in microglia can prevent this destruction.
However, even though MPP+ directly targets DA neurons
to produce toxicity, SN still shows a significant protective
effect in these cultures as well. This is most likely due to
the fact that a significant portion of the MPP+-mediated
neurotoxicity requires the presence of microglial cells,
suggesting that MPP+ works both directly to kill a subset of
DA neurons, but also indirectly to activate microglia
through reactive microgliosis. Recent evidence indicates
that neuronal death or damage triggers activation of
microglia through either release of soluble factors or loss
of cell-cell contact inhibition between neurons and micro-
glia [27,39]. This activation of microglia by dying neurons
then continuously damages the remaining DA neurons,
and creates a self-propelling inflammatory cycle, which
may underlie the progressive nature of neurodegenerative
diseases such as PD. Reports from our laboratory and oth-
ers have indicated that MPP+ can cause reactive microglio-
sis, and that oxidative stress is involved in MPTP/MPP+ -
induced neurotoxicity [27,40]. Our observation that
MPP+-mediated neurotoxicity is significantly less in
PHOX-/- animals [41], and that SN does not protect DA
neurons from MPP+-mediated toxicity in neuron-enriched
or neuron-astroglial cultures (Fig. 3), supports the notion
that SN protects MPP+-induced neurotoxicity mainly
through the inhibition of ROS production, which in turn
slows down the self-propelling cycle and prevents further
neuronal death. In addition, although LPS and MPP+
work in different ways to produce neurotoxicity, the death
of neurons induced by both LPS and MPP+ will further
activate microglia through the process of reactive micro-
gliosis, in which superoxide plays a critical role.
Conclusion
In summary, this study is the first report indicating that
SN is a potent anti-inflammatory and neuroprotective
agent that acts through inhibition of microglial PHOX-
generated superoxide by inhibiting the translocation of
p47phox to the plasma membrane. We have previously
reported that several morphinan compounds, such as
naloxone, exert their neuroprotective effects independent
of the conventional opioid receptors [18,22], because the
dextrorotatory form of this compound, which binds
poorly to the opioid receptors, is equipotent with its levo-
rotatory isomer. SN, being a natural dextrorotatory form
of morphinan that can be easily extracted and purified
from its herb plant, is an ideal alternative for other synthe-
sized dextrorotatory form morphinan compounds since
the dextrorotatory isomers are extremely expensive to fab-
ricate. In view of its potent anti-inflammatory and neuro-
protective effects, its safe record of clinical usage to treat
rheumatoid arthritis, and its relatively low cost, SN is an
ideal candidate for animal and clinical trial studies to
evaluate its therapeutic potential as a neuroprotective
agent for PD and other inflammation-related neurode-
generative diseases.
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